ClinicalTrials.gg
RecruitingNCT03992625Updated Jun 20, 2019

Clinical Outcomes for Deep Brain Stimulation

An observational study in Parkinson Disease, Essential Tremor and Dystonia, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2019-06-20.

Sponsored by Washington University School of Medicine · Observational

How we know

From the registry’s dates

  • Started Jan 2011; still recruiting 15 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Parkinson Disease by Washington University School of Medicine — 7 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Washington University School of Medicine.

Planned enrollment
Largest of 13
1,000 · median 174
Started
2011
with 1 other
Observational
13 of 32
6 open now
Registered
16th of 32
by date

Among the 32 studies in Parkinson Disease by Washington University School of Medicine, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2011, is one of 13 observational ones, and was the 16th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

7 of the 32 studies in Parkinson Disease by Washington University School of Medicine are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Parkinson Disease by Washington University School of Medicine, or all of them as a file.
02

Study summary

The object of this study is to longitudinally collect clinical outcomes of patients receiving deep brain stimulation for movement disorders with the objective of making retrospective comparisons and tracking of risks, benefits, and complications.

03

Conditions studied

  • Parkinson Disease
  • Essential Tremor
  • Dystonia

Keywords

  • Deep brain stimulation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients receiving deep brain stimulation for movement disorders

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Levodopa responsive Parkinson disease OR
  • Medically Essential Tremor OR
  • Medically refractory Dystonia

Exclusion criteria

Exclusion Criteria:

  • Dementia (Mattis Dementia Rating Scale \<130)
  • Structural abnormalities precluding intracranial surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Interventions

  • DeviceDeep Brain Stimulation

    High frequency electrical stimulation of deep brain nuclei for the treatment of movement disorders

06

What researchers measure

Primary outcomes

  1. UPDRS

    United Parkinson's Disease Rating Scale (global assessment of motor, non-motor, and quality of life associated with symptoms of Parkinson disease). Total scores range from 0-199. Particular emphasis is paid to subsection 3 (motor), where scores range from 0-56.

    Time frame: Change in UPDRS at 1 year after DBS (from preoperative baseline).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2011 (actual). Primary completion is estimated for Jan 2030, 227 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2019
First posted
Jun 20, 2019
StartActual
Jan 3, 2011
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Jun 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03992625
Responsible party
Mwiza Ushe (Assistant Professor, Washington University School of Medicine) — Principal investigator
First posted
Jun 20, 2019
Start date
Jan 3, 2011
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Jun 20, 2019

Study contacts

Mwiza Ushe, M.D.
Contact
ushem@wustl.edu
3143625262
Mwiza Ushe, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion